Relmada Therapeutics (RLMD) Non-Current Debt (2017 - 2018)
Relmada Therapeutics (RLMD) reported Non-Current Debt of $3.2 million for Q3 2018, up 370.33% year-over-year from $678875.0 in Q3 2017, and up 20.2% on a QoQ basis from $2.7 million in Q2 2018.
Relmada Therapeutics (RLMD) has 2 years of Non-Current Debt data on file, last reported at $3.2 million in Q3 2018.
- Quarterly Non-Current Debt rose 370.33% year-over-year to $3.2 million in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $3.2 million (up 370.33% YoY) and the FY2018 annual result came in at $2.7 million, changed N/A from the prior year.
- Non-Current Debt advanced to $3.2 million in Q3 2018 per RLMD's latest filing, from $2.7 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $3.2 million in Q3 2018 and bottomed at $678875.0 in Q3 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 105.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 3.19 Mn |
| Sep 30, 2018 | 3.19 Mn |
| Jun 30, 2018 | 2.66 Mn |
| Jun 30, 2018 | 2.66 Mn |
| Mar 31, 2018 | 1.58 Mn |
| Mar 31, 2018 | 1.58 Mn |
| Dec 31, 2017 | 1.28 Mn |
| Dec 31, 2017 | 1.28 Mn |
| Sep 30, 2017 | 678,875.00 |
| Sep 30, 2017 | 678,875.00 |